Cardiomyocyte–endothelial cell interactions

Endothelial Biomedicine

Volumn , Issue , 2007, Pages 602-608

  Li, Jian ^a   Sellke, Frank W ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69549143998     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546198.066     Document Type: Chapter

References (79)

1. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83:59–115.
2. Brutsaert DL, Fransen P, Andries LJ, et al. Cardiac endothelium and myocardial function. Cardiovasc Res. 1998;38:281–290.
3. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res. 1988;62:358–366.
4. Li K, Rouleau JL, Andries LJ, Brutsaert DL. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res. 1993;72:768–777.
5. Li K, Qi X, Andries L, et al. Vascular-derivedmyocardial contractile factor: positivemyocardial inotropic substance released from medial layer of the canine aorta. J Mol Cell Cardiol. 1996;28:881– 892.
6. Kuruvilla L, Kartha CC. Molecular mechanisms in endothelial regulation of cardiac function. Mol Cell Biochem. 2003;253:113– 123.
7. Winegrad S. EC regulation of contractility of the heart. Annu Rev Physiol. 1997;59:505–525.
8. Winegrad S, Henrion D, Rappaport L, Samuel JL. Vascular EC-cardiac myocyte crosstalk in achieving a balance between energy supply and energy use. Adv Exp Med Biol. 1998;453:507–514.
9. Aird WC, Edelberg JM, Weiler-Guettler H, et al. Vascular bedspecific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol. 1997;138:1117–1124.
10. Lindner V. Expression of platelet-derived growth factor ligands and receptors by rat aortic endothelium in vivo. Pathobiology. 1995;63:257–264.
11. D’Amore PA, Smith SR. Growth factor effects on cells of the vascular wall: a survey. Growth Factors. 1993;8:61–75.
12. Wang CY, Naka Y, Liao H, et al. Cardiac graft intercellular adhesion molecule-1 (ICAM-1) and interleukin-1 expression mediate primary isograft failure and induction of ICAM-1 in organs remote from the site of transplantation. Circ Res. 1998;82:762– 772.
13. Salom RN, Maguire JA, Hancock WW. Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology. 1998;30:24–29.
14. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15–35.
15. Ferrara N, Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS. 1997;79:209–232.
16. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126: 1149–1159.
17. Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res. 1999;59:3185–3191.
18. Jendreyko N, Popkov M, Beerli RR, et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem. 2003;278: 47812–47819.
19. Jendreyko N, Popkov M, Rader C, Barbas CF. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA. 2005;102:8293–8298.
20. Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 1996;270:H1803–H1811.
21. Wu G, Mannam AP, Wu J, et al. Hypoxia induces myocytedependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol. 2003;285:H2420–H2429.
22. Zhang Y, Pasparakis M, Kollias G, Simons M. Myocyte-dependent regulation of ECsyndecan-4 expression.Role of TNF-alpha. J Biol Chem. 1999;274:14786–14790.
23. Wilkinson-Berka JL.Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des. 2004;10:3331–3348.
24. Wu G, Luo J, Rana JS, et al. Involvement of COX-2 in VEGFinduced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res. 2006;69:512-519
25. Horowitz A, Simons M. Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J Biol Chem. 1998;273:25548–25551.
26. Simons M, Horowitz A. Syndecan-4-mediated signalling. Cell Signal. 2001;13:855–862.
27. Keum E, Kim Y, Kim J, et al. Syndecan-4 regulates localization, activity and stability of protein kinase C-alpha. Biochem J. 2004; 378:1007–1014.
28. Zhang Y, Li J, Partovian C, et al. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol. 2003;284:H2078–H2082.
29. Partanen J, Puri MC, Schwartz L, et al. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development. 1996;122:3013–3021.
30. Puri MC, Partanen J, Rossant J, Bernstein A. Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development. 1999;126:4569–4580.
31. Puri MC, Rossant J, Alitalo K, et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 1995;14:5884–5891.
32. Kardami E, Fandrich RR. Basic fibroblast growth factor in atria and ventricles of the vertebrate heart. J Cell Biol. 1989;109:1865– 1875.
33. Price RJ, Skalak TC. Circumferential wall stress as a mechanism for arteriolar rarefaction and proliferation in a network model. Microvasc Res. 1994;47:188–202.
34. Fan J, Walsh KB. Mechanical stimulation regulates voltage-gated potassium currents in cardiac microvascular endothelial cells. Circ Res. 1999;84:451–457.
35. Heymes C, Vanderheyden M, Bronzwaer JG, et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation. 1999;99:3009–3016.
36. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595–606.
37. Mohacsi A, Magyar J, Tamas B, Nanasi PP. Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr Vasc Pharmacol. 2004;2:53–63.
38. Shah AM, Grocott-Mason RM, Pepper CB, et al. The cardiac endothelium: cardioactive mediators. Prog Cardiovasc Dis. 1996; 39:263–284.
39. Mebazaa A, Wetzel RC, Dodd-o JM, et al. Potential paracrine role of the pericardium in the regulation of cardiac function. Cardiovasc Res. 1998;40:332–342.
40. Levin ER. Endothelins as cardiovascular peptides. Am J Nephrol. 1996;16:246–251.
41. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363.
42. Russell FD, Skepper JN, Davenport AP. Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res. 1998;83:314–321.
43. Mebazaa A, Mayoux E, Maeda K, et al. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am J Physiol. 1993;265:H1841–H1846.
44. Suzuki E, Nagata D, Kakoki M, et al. Molecular mechanisms of endothelin-1-induced cell-cycle progression: involvement of extracellular signal-regulated kinase, protein kinase C, and phosphatidylinositol 3-kinase at distinct points. Circ Res. 1999;84: 611–619.
45. Kramer BK, Nishida M, Kelly RA, Smith TW. Endothelins. Myocardial actions of a new class of cytokines. Circulation. 1992;85: 350–356.
46. Pohl U, Busse R. Hypoxia stimulates release of endotheliumderived relaxant factor. Am J Physiol. 1989;256:H1595–H1600.
47. Katusic ZS, Shepherd JT. Endothelium-derived vasoactive factors: II. Endothelium-dependent contraction. Hypertension. 1991;18:III86–III92.
48. Vanhoutte PM, Luscher TF, Graser T. Endothelium-dependent contractions. Blood Vessels. 1991;28:74–83.
49. Pearson PJ, Lin PJ, Schaff HV. Production of endotheliumderived contracting factor is enhanced after coronary reperfusion. Ann Thorac Surg. 1991;51:788–793.
50. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002;3:1–15.
51. Fedak PW, Rao V, Verma S, et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg. 2005; 129:407–415.
52. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: anewtherapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493–1505.
53. Nishida M, Springhorn JP, Kelly RA, Smith TW. Cell-cell signaling between adult rat ventricular myocytes and cardiac microvascular endothelial cells in heterotypic primary culture. J Clin Invest. 1993;91:1934–1941.
54. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999;85: 643–650.
55. Dostal DE, Baker KM. Angiotensin and endothelin: messengers that couple ventricular stretch to the Na+/H+ exchanger and cardiac hypertrophy. Circ Res. 1998;83:870–873.
56. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988;77:I4–I13.
57. Fischer TA, Ungureanu-Longrois D, Singh K, et al. Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells. Am J Physiol. 1997;272:H958– H968.
58. Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensinconverting enzymeinhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemiareperfusion. Circulation. 1996;93:544–551.
59. Andries LJ, Brutsaert DL, Sys SU. Nonuniformity of endothelial constitutive nitric oxide synthase distribution in cardiac endothelium. Circ Res. 1998;82:195–203.
60. Smith JA, Shah AM, Lewis MJ. Factors released from endocardium of the ferret and pig modulate myocardial contraction. J Physiol. 1991;439:1–14.
61. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575–580.
62. Gudi SR, Clark CB, Frangos JA. Fluid flow rapidly activates G proteins in human endothelial cells. Involvement of G proteins in mechanochemical signal transduction. Circ Res. 1996;79: 834–839.
63. Cohen CR, Mills I, Du W, et al. Activation of the adenylyl cyclase/cyclic AMP/protein kinaseApathway in endothelial cells exposed to cyclic strain. Exp Cell Res. 1997;231:184–189.
64. Pulinilkunnil T, An D, Yip P, et al. Palmitoyl lysophosphatidylcholine mediated mobilization of LPL to the coronary luminal surface requires PKC activation. J Mol Cell Cardiol. 2004;37:931– 938.
65. Tseng H, Peterson TE, Berk BC. Fluid shear stress stimulates mitogen-activated protein kinase in endothelial cells. Circ Res. 1995;77:869–878.
66. Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347–351.
67. Kubota I, Han X, Opel DJ, et al. Increased susceptibility to development of triggered activity inmyocytes frommicewith targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol. 2000;32:1239–1248.
68. Mebazaa A, Wetzel R, Cherian M, Abraham M. Comparison between endocardial and great vessel endothelial cells: morphology, growth, and prostaglandin release. Am J Physiol. 1995;268:H250–H259.
69. Hendrickson RJ, Cappadona C, Yankah EN, et al. Sustained pulsatile flow regulates endothelial nitric oxide synthase and cyclooxygenase expression in co-cultured vascular endothelial and smooth muscle cells. J Mol Cell Cardiol. 1999;31:619– 629.
70. Gerritsen ME. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res. 1996;32: 720–732.
71. Narmoneva DA, Vukmirovic R, Davis ME, et al. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation. 2004;110: 962–968.
72. McClellan G, Weisberg A, Rose D, Winegrad S. Endothelial cell storage and release of endothelin as a cardioregulatory mechanism. Circ Res. 1994;75:85–96.
73. McClellan G, Weisberg A, Winegrad S. Effect of endothelin-1 on actomyosin ATPase activity. Implications for the efficiency of contraction. Circ Res. 1996;78:1044–1050.
74. Shah AM, Mebazaa A, Wetzel RC, Lakatta EG. Novel cardiac myofilament desensitizing factor released by endocardial and vascular ECs. Circulation. 1994;89:2492–2497.
75. McClellan G, Weisberg A, Kato NS, et al. Contractile proteins in myocardial cells are regulated by factor(s) released by blood vessels. Circ Res. 1992;70:787–803.
76. Ramaciotti C, McClellan G, Sharkey A, et al. Cardiac endothelial cells modulate contractility of rat heart in response to oxygen tension and coronary flow. Circ Res. 1993;72: 1044–1064.
77. Wang JX, Paik G, Morgan JP. Endothelin 1 enhancesmyofilament Ca2+ responsiveness in aequorin-loaded ferretmyocardium. Circ Res. 1991;69:582–589.
78. Margulies KB, Hildebrand FL., Lerman A, et al. Increased endothelin in experimental heart failure. Circulation. 1990;82: 2226–2230.
79. Brutsaert DL, De Keulenaer GW, Fransen P, et al. The cardiac endothelium: functional morphology, development, and physiology. Prog Cardiovasc Dis. 1996;39:239–262.